GLMD Galmed Pharmaceuticals Ltd.
Healthcare$0.63+8.60%ClosedMarket Cap: $3.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.24
P/S
0.00
EV/EBITDA
0.09
DCF Value
$0.51
FCF Yield
-198.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.0%
ROA
-55.3%
ROIC
-53.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 null | $0.00 | NaN% | $-3.0M | $-4.8M | $— | — |
| FY null | $0.00 | NaN% | $-8.5M | $-10.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.1M | $-1.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.1M | $-2.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.3M | $-1.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.6M | $-3.2M | $— | — |
| FY null | $0.00 | NaN% | $-6.3M | $-7.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.0M | $-1.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.2M | $-1.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.4M | $-1.3M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.2M | $-2.0M | $-0.40 | — |
| FY null | $0.00 | NaN% | $-7.5M | $-6.9M | $— | — |